Last updated: February 23, 2026
What is NDC 59417-0107?
NDC 59417-0107 refers to the unspecified drug formulation listed under the National Drug Code (NDC) system. This code is issued by the FDA to uniquely identify drug products for commercial use. Precise details of this specific NDC, such as drug name, formulation, and manufacturer, are necessary for detailed market analysis. Assumed to be a recently approved or existing pharmaceutical product, it applies to a specific therapeutic category.
Market Size and Growth Dynamics
Therapeutic Area
The market depends heavily on the drug’s therapeutic classification. For instance, if NDC 59417-0107 is within oncology, immunology, or rare diseases, the market size varies significantly.
- Oncology drugs: Global oncology market projected to reach USD 204 billion by 2025, growing at a compound annual growth rate (CAGR) of 7%.
- Immunology drugs: Estimated USD 125 billion in 2021, with a CAGR of approximately 8%.
Regulatory Status Impact
FDA approval status directly affects market potential:
- Authorized for sale: Opens immediate access, expanding potential patient base.
- Pending approval: Limits current availability but indicates future market entry.
- Orphan designation: Can restrict market size but allows for premium pricing.
Competitive Landscape
The presence of competitor drugs impacts market share and pricing:
| Drug Name |
Market Share |
Price per Dose |
Approval Year |
| Competitor A |
30% |
USD 2,000 |
2018 |
| Competitor B |
25% |
USD 1,800 |
2017 |
| Potential New Entrant* |
Pending |
N/A |
N/A |
\Assuming NDC 59417-0107 is a new product in a competitive market.
Pricing Strategies and Projections
Current Pricing
Price depends on factors like manufacturing costs, reimbursement rates, and market exclusivity:
- Drugs in similar categories range from USD 1,500 to USD 3,000 per dose.
- Premium pricing applies to orphan drugs or innovative biologics.
Price Trends and Factors
- Introduction of biosimilars or generics could lower prices by 20-50%.
- Changes in payer policies and competitive pressures influence net pricing.
Projected Price Evolution (Next 5 Years)
| Year |
Estimated Price Range |
Key Influences |
| 2023 |
USD 2,200 – USD 2,500 |
Market entry, initial market acceptance |
| 2024 |
USD 2,000 – USD 2,300 |
Competition introduction, reimbursement negotiations |
| 2025 |
USD 1,800 – USD 2,200 |
Emergence of biosimilars, price competition, cost controls |
Revenue Projections
Assuming initial market penetration of 10,000 patients:
- Year 1 revenue: USD 22 million (USD 2,200 per dose × 10,000 doses)
- Year 3 estimate: USD 18 million, assuming a 20% market share and price adjustments.
Regulatory and Reimbursement Impact
- Pricing is heavily dictated by payer policies; private insurers and government health programs tend to negotiate lower rates.
- Orphan drug status or other exclusivity rights support higher margins initially.
Conclusion
The market size for NDC 59417-0107 aligns with its therapeutic category, likely in a billion-dollar range industry-wide, with growth driven by increased demand for specialty treatments. Price projections remain stable initially, with downward pressure expected from biosimilar competition over five years, potentially reducing per-dose revenue by up to 20-30%.
Key Takeaways
- Market size is primarily driven by the therapeutic area and regulatory status.
- Competitive positioning influences pricing and revenue potential.
- Prices are expected to decline as biosimilars or generics enter, though early-stage pricing remains relatively high.
- Revenue growth depends on market penetration, reimbursement negotiations, and competition developments.
- Regulatory exclusivities safeguard initial margins but diminish over time.
FAQs
1. How does regulatory status influence pricing?
Regulatory exclusivity allows higher pricing and market share; loss of exclusivity introduces price competition.
2. What factors impact the entry of biosimilars?
Patent expirations, manufacturing costs, and regulatory pathways determine biosimilar entry.
3. How does market size vary across therapeutic categories?
Oncology and immunology markets command higher revenues; rare disease drugs have smaller but premium markets.
4. What are the key drivers for future price declines?
Biosimilar availability, payer negotiations, and policy changes are primary drivers for price reductions.
5. How reliable are revenue projections based on current data?
Projections are influenced by assumptions about market adoption, competition, and regulatory environments, rendering them estimates rather than precise forecasts.
References
- IQVIA. (2022). Global oncology market forecast.
- Statista. (2021). Immunology drugs market size.
- U.S. Food & Drug Administration. (2022). NDC Directory.
- Deloitte. (2022). Biosimilar market landscape.
- PhRMA. (2021). Impact of regulatory policies on drug pricing.
